StemCell Therapy

during the forecast period. The growth in this market is attributed to technological advancements in single-cell analysis products, increasing government funding for cell-based research, growing biotechnology and biopharmaceutical industries, wide applications of single-cell analysis in cancer research, growing focus on personalized medicine, and the increasing incidence and prevalence of chronic and infectious diseases.

New York, Feb. 28, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Single-cell Analysis Market by Cell Type, Product, Technique, Application, End User - Global Forecasts to 2025" - https://www.reportlinker.com/p04579530/?utm_source=GNW However, the high cost of single-cell analysis products is expected to restrain the growth of this market to a certain extent during the forecast period.

The academic & research laboratories segment accounted for the largest market share in 2018On the basis of end user, the single-cell analysis market is segmented into academic and research laboratories, biotechnology and pharmaceutical companies, hospitals and diagnostic laboratories, and cell banks and IVF centers.The academic and research laboratories segment accounted for the largest market share in 2018.

Factors such as growth in funding for life science research and the increasing number of medical colleges and universities are driving the growth of this end-user segment.

Flow cytometry is the largest technique segment of the single-cell analysis marketBased on technique, the single-cell analysis market is segmented into flow cytometry, NGS, PCR, microscopy, mass spectrometry, and other techniques.The flow cytometry segment accounted for the largest market share in 2018.

The large share of this segment is attributed to the wide usage of flow cytometry in detecting and measuring the physical and chemical characteristics of a population of cells or particles.

North America will continue to dominate the single-cell analysis market in 2025The single-cell analysis market, by region, is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.In 2018, North America accounted for the largest share of the single-cell analysis market.

The large share of North America can be attributed to the increasing drug development activities in the pharmaceutical and biotechnology industries, rising prevalence of chronic and infectious diseases, and an increase in stem cell research activities.

The breakup of primary participants is as mentioned below: By Company Type - Tier 1: 45%, Tier 2: 30%, and Tier 3: 25% By Designation - C-level: 35%, Director-level: 25%, and Others: 40% By Region - North America: 40%, Europe: 20%, Asia Pacific: 25%, Latin America: 10%, and the Middle East & Africa: 5%

Prominent players in the single-cell analysis market include Becton, Dickinson and Company (US), Danaher Corporation (US), Merck Millipore (US), QIAGEN (Netherlands), Thermo Fisher Scientific (US), General Electric Company (US), 10x Genomics (US), Promega Corporation (US), Illumina (US), Bio-Rad Laboratories (US), Fluidigm Corporation (US), Agilent Technologies (US), NanoString Technologies (US), Tecan Group (Switzerland), Sartorius AG (Germany), Luminex Corporation (US), Takara Bio (Japan), Fluxion Biosciences (US), Menarini Silicon Biosystems (Italy), and LumaCyte (US).

Research Coverage:The report analyzes the single-cell analysis market and aims at estimating the market size and future growth potential of this market based on various segments such as product, cell type, technique, application, end user, and region. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, recent developments, and key market strategies.

Reasons to Buy the ReportThe report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their positions in the market.

This report provides insights into: Market Penetration: Comprehensive information on the product portfolios of the top players in the single-cell analysis market. The report analyzes this market by product, application, cell type, technique, end user, and region Market Development: Comprehensive information on the lucrative emerging markets by product, application, cell type, technique, end user, and region Market Diversification: Exhaustive information about products, growing geographies, recent developments, and investments in the single-cell analysis market Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of leading players in the single-cell analysis marketRead the full report: https://www.reportlinker.com/p04579530/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Story continues

Clare: clare@reportlinker.comUS: (339)-368-6001Intl: +1 339-368-6001

Excerpt from:
The global single-cell analysis market is projected to reach USD 5.6 billion by 2025 from USD 2.1 billion in 2019, at a CAGR of 17.8% - Yahoo Finance

Machine learning is helping Penn Medicine researchers identify the size and shape of brain networks in individual children, which may be useful for understanding psychiatric disorders. In a new study publishedin the journalNeuron,a multidisciplinary team showed how brain networks unique to each child can predict cognition. The study, which used machine learning techniques to analyze the functional magnetic resonance imaging (fMRI) scans of nearly 700 children, adolescents, and young adults, is the first to show that functional neuroanatomy can vary greatly among kids, and is refined during development.

The human brain has a pattern of folds and ridges on its surface that provide physical landmarks for finding brain areas. The functional networks that govern cognition have long been studied in humans by liningup activation patternsthe software of the brainto the hardware of these physical landmarks. However, this process assumes that the functions of the brain are located on the same landmarks in each person. This works well for many simple brain systems. However, multiple recent studies in adults have shown this is not the case for more complex brain systems responsible for executive functiona set of mental processes which includes self-control and attention. In these systems, the functional networks do not always line up with the brains physical landmarks of folds and ridges. Instead, each adult has their own specific layout. Until now, it was unknown how such person-specific networks might change as kids grow up, or relate to executive function.

The exciting part of this work is that we are now able to identify the spatial layout of these functional networks in individual kids, rather than looking at everyone using the same one size fits all approach, says senior authorTheodore D. Satterthwaite, an assistant professor of psychiatry in the Perelman School of Medicine. Like adults, we found that functional neuroanatomy varies quite a lot among different kidseach child has a unique pattern. Also like adults, the networks that vary the most between kids are the same executive networks responsible for regulating the sorts of behaviors that can often land adolescents in hot water, like risk taking and impulsivity.

Read more at Penn Medicine News.

The rest is here:
Machine learning identifies personalized brain networks in children - Penn: Office of University Communications

Michael Vi / Shutterstock

Shares of Iovance Biotherapeutics shot up Tuesday on rumors the company could be up for sale. The news comes a day after the company said it intends to speak with regulatory agencies later this year about its programs in melanoma and cervical cancer.

First reported by Bloomberg, Iovance is reportedly working with a financial adviser about a potential sale following conversations about a potential takeover from a larger company. The information was provided by unidentified sources who are familiar with the matter, Bloomberg said. The news sent shares of Iovance up more than 30% in Tuesdays trading. Part of that boost was due to the companys fourth-quarter progress in its clinical pipeline. In anticipation of potential approval and commercialization of its lead candidates, Iovance said it was building its internal manufacturing capability, as well as expanding its commercial team and infrastructure.

While nothing has been formally stated, Benjamin Burnett, an analyst with Stifel Financial Inc. said in a note that acquiring Iovance would make sense for some companies, including Takeda Pharmaceutical and Gilead Sciences, Bloomberg reported. This morning, Takeda announced its intention to acquire celiac disease-focused PvP Biologics for $330 million to complement its gastrointestinal pipeline. Burnett said Iovance is one of the few cell therapy companies in the coverage of Stifel Financial that has been de-risked to a large degree by a proof-of-concept study. Because of that, Burnett said they can see how this might be one of the more interesting cell therapy take-out candidates.

Despite the potential for an acquisition, Iovance could opt to remain independent, the unidentified sources told Bloomberg. A representative for Iovance declined to comment, Bloomberg added.

San Carlos, Calif.-based Iovance specializes in cell therapy focused on treating solid tumors with tumor infiltrating lymphocyte (TIL) therapies. In a previous interview with BioSpace, Iovance Chief Executive Officer Maria Fardis explained that TIL technology is a boosting of the bodys natural immunity. The TIL is removed from a cancerous tumor, amplified in number through cell culture to attack the disease, then are reinserted into the tumor to do the work. Because the amplified TILs can attack the whole tumor, including any potential mutations, Fardis described it as the most exquisite kind of personalized medicine for a patient.

Iovances investigational candidates include lifileucel, which is being investigated as a potential treatment for melanoma and LN-145, a potential treatment for patients with recurrent, metastatic or persistent cervical carcinoma. Lifileucel has received both fast-track and regenerative medicine advanced therapy from the U.S. Food and Drug Administration in melanoma, a common type of skin cancer, accounting for approximately 96,000 patients diagnosed annually and 7,200 deaths each year in the United States, Fardis said in a call with analysts Tuesday, according to transcripts.

In its most recent announcement regarding lifileucel in melanoma, the company reported an overall response rate (ORR) of 36.4% in 66 patients who were heavily pretreated.

The company is enrolling patients in a second pivotal study of LN-145 in patients with metastatic cervical cancer. During 2019, LN-145 received breakthrough therapy designation or BTD, as well as fast-track designation from the FDA. These designations were supported by compelling data demonstrating a 44% ORR from 27 patients in the ongoing study, Fardis said.

Read more:
Report: Iovance Exploring Potential Sale of the Company - BioSpace

The various technologies that make up IT infrastructure are the foundation for all the other forms of health IT that make hospitals and health systems operate effectively. As such, infrastructure technologies are among the most important in the healthcare information technology arena, and they must be operating optimally.

Here, three infrastructure technology experts from Cisco Systems, Dell Technologies and VMware offer best practices for optimizing infrastructure so that it is working best for individual healthcare provider organizations. They target their advice at healthcare CIOs and other health IT leaders who are looking to make sure their infrastructure is rock solid and humming along smoothly.

To fully optimize infrastructure, IT needs to plan for the entire business transformation journey to include reimagining their apps for the patient/clinician experience and then build the infrastructure for those experiences, said Kathryn Howe, Cisco healthcare director, Americas industry digital transformation.

Patients today need humanized experiences from healthcare providers, personalized interactions, easy access to information, and on-demand responses from clinicians, she explained. To keep up with the ever-changing patient needs, healthcare organizations are becoming more digitized, offering new apps and more. Adopting new technologies can create as many challenges as advantages if organizations focus only on optimizing IT infrastructure. IT needs a digital transformation framework to succeed.

Kathryn Howe, Cisco Systems

Integrating, securing and optimizing the IT infrastructure is the first step in the digital transformation framework, she said.

Its the enablement stage where healthcare providers optimize their IT infrastructures to digitize existing services, she noted. This step will streamline and enhance employee and customer experiences through primary offerings such as home care services, mobile engagement and location-based analytics. With the infrastructure in place, CIOs get to optimize their resources to deliver more value, such as implementing personalized engagement strategies, offering online support groups and virtual services.

The IT infrastructure is fully optimized when it is being used to power the organizations most sophisticated endeavors, she added, from new business models to disruptive digital experiences like AI-driven patient scheduling and predictive analytics.

On another front, typically, when a healthcare provider organization is looking to invest in an IT optimization project, it first considers its internal resources, specifically budget and the potential for staff disruption, said David Dimond, healthcare and life sciences chief innovation officer at Dell Technologies.

We can learn from some of the recent rocky implementations of electronic health records in which budgets exceeded expectations and significant delays were experienced in implementation and integration, he stated. According to one survey, 56% of respondentsdidnt believe that the challenges of adopting a new EHR system were equal to, or outweighed, the benefits of integration.

David Dimond, Dell Technologies

Examples like these have made healthcare organization boards circumspect in investing in digital health projects, Dimond contended.

This thinking is unfortunate, as some infrastructure optimizations can free up resources to invest in innovation, as is the case with multi-cloud deployment, he explained. Adopting, or optimizing, a multi-cloud infrastructure allows healthcare organizations to capture, process and access data significantly faster wherever it resides improving everything from patient care delivery to billing.

Just as every healthcare provider organization must have its own specific business model, each companys cloud strategy must match its specific clinical and business workload needs, he asserted.

Cloud strategies are ever-evolving, not simple one-off solutions, he said. Multi-cloud solutions have come a long way you adopt a hybrid cloud environment with an integrated cloud infrastructure compute, storage, networking and security that runs on premises and in public clouds. Organizations should expect consistent operations with infrastructure across private and public cloud, and the edge for a true hybrid cloud experience that is seamless to its end users.

For example, on-premises solutions may be optimal for certain workloads and ideal in terms of risk reduction and monitoring, while off-premises solutions offer better manageability, ease of procurement and cost, he said.

For this reason, every healthcare provider must decide their own workload priorities and optimize their cloud strategy to match the best location for data and applications, he said. A multi-cloud infrastructure provides a single pane of glass to identify and monitor the data across the healthcare ecosystem, simplifying intelligence at the point of care and collaboration among clinicians.

Christopher Logan, director of healthcare industry strategy at VMware, offers another best practice when optimizing infrastructure technology: operational automation.

Automation in healthcare, when coupled with emerging technologies like AI, does not get its fair amount of press or headlines, he said. When applying automation across/within the infrastructure, basic operational tasks and administration can result in a number of efficiencies like better patient experience, greater employee satisfaction, increased quality of services, improved project delivery and a significant reduction in cost.

Christopher Logan, VMware

Another best practice, he said, is workforce transformation.The workforce is constantly evolving, due to factors such as technological advancements and the demand for new skill sets.

Coupled with the fact that employees today have high expectations for their digital experiences, workforce transformation is critical in achieving broader digital transformation, he explained. It is imperative that all healthcare organizations find the right tools and technologies that provide employees with flexibility and secure access to ease IT management burdens and improve productivity.

This does not stop there, as providing a consistent user experience has the capability to transform both the patient and employee experience, which is critical for engagement and retention, he added.

When it comes to optimizing infrastructure, cybersecurity strategies need to permeate infrastructure as well as all levels of a healthcare provider organization, said Howe of Cisco.

Todays CIOs face more than the risk of costly data breaches, she said. Failing to meet standards like HIPAA can result in fines for up to $1.5 million per year. In order to protect patient data and meet compliance standards, CIOs need to enforce a strategy that permeates all layers of the organization, from technologies to the people.

At the network level, a fully integrated secure IT infrastructure will be key to enabling IT teams to maintain a pulse on all activities in real time and address potential risks before they occur, she advised.

An effective tactic is using micro-segmentation to limit the spread of attacks between devices and across the network by creating profiles, policies and permissions that are specific to those devices, reducing unauthorized access for all users, she said.

At the user level, it is vital to empower and train teams to keep data secure.

Implementing two-factor authentication platforms for patients, healthcare staff and third-party vendors should be a non-negotiable, and can help organizations stay compliant and safe by ensuring that only trusted users and devices can access certain sensitive applications or data, she cautioned. This is especially important as more healthcare organizations adopt remote access technologies and devices to deliver seamless connected experiences to patients and streamline workflows for clinicians.

Logan of VMware agrees with Howe that cybersecurity must be a big part of infrastructure optimization.

Sophistication and frequency of cyberattacks are increasingly placing a strain across all sectors, especially in healthcare, he noted. In order to navigate these complex and dynamic environments, healthcare organizations and their leaders must have a strong investment in digital technologies, and an even larger investment on cybersecurity strategies.

A proactive cybersecurity strategy and shift needs to continue happening across healthcare to protect patient data from security threats, ensuring the availability and integrity of critical healthcare workloads, he added.

Elsewhere, he said that hybrid and public cloud migration is an important part of infrastructure optimizxation.

Organizations across all industries are increasingly adopting hybrid and public cloud models, due to its offerings of scalability, agility and speed to market, he said. By making use of cloud solutions whether from Google, Amazon, Microsoft or another provider healthcare providers can simply scale the technical resources needed to run critical applications and drive cost savings.

At the same time, this is preparing those providers to adopt IT modernization to deliver dynamic on-demand services to meet the needs of their workforce and patients, he added.

The Internet of Things is a big part of healthcare IT infrastructure. An emerging focus for healthcare organizations is building out their IoT strategy.

IoT and edge solutions have been adopted by consumers, most notably, fitness trackers and smartwatches, said Dimond of Dell Technologies. A study by Statistafound that more than 56.7 million people wore wearables like smartwatches and Fitbits in 2019. This market will continue to grow and analysts predict the number of users will increase to 67 million people in 2022.

In an acute care setting, there are 10-15 connected devices for every U.S. hospital bed, which creates a significant amount of data, he noted. Overall, healthcare data grew 878%from 2016 to 2018, with much of it coming from sensors, wearables and mobile apps for preventative care and chronic disease management.

However, it is one thing to generate all this data, and quite another challenge to digest it all and generate patient insights. Healthcare providers are investing in distributed analytics to improve patient safety and monitor recovery, expand chronic disease management, enhance precision medicine through research, and manage pharmaceutical supply safety just to name a few applications, Dimond said.

Real-time analytics at the edge creates an opportunity to identify, refine and understand the data where it originates, for the fastest possible insights and action, he said. To support the distributed network of data-driven devices, healthcare organizations require a multi-faceted approach.

As healthcare provider organizations build their edge and IoT strategy, they need to evaluate their unique multi-cloud approach in parallel with specific application workloads, he advised.

Depending on classification, some data such as EHRs, laboratory information systems and clinical decision application data may be stored on-premises, he concluded. Other data may be stored in the cloud whether private, public or hybrid. It is important to consider how data can flow securely and efficiently from the edge to the data center and to multiple clouds.

Twitter:@SiwickiHealthITEmail the writer:bill.siwicki@himssmedia.comHealthcare IT News is a HIMSS Media publication.

View original post here:
Tech optimization: Keeping infrastructure tech rock solid - Healthcare IT News

ST. PETERSBURG, Fla.--(BUSINESS WIRE)--InformedDNA, the nations largest independent provider of genetics services, today announced the addition of healthcare industry veterans to its executive leadership team and its board of directors. Paul Danao has joined the company as chief growth officer, responsible for driving revenue growth and retention through sales, marketing and client management. Dr. Jacqueline Kosecoff, a renowned healthcare industry expert, has joined InformedDNAs board as an independent director.

Founded in 2007, InformedDNA was the first company in the U.S. to use telephonic services to connect genetic counselors to patients. Since then, it has expanded to provide technology-led services to patients, healthcare providers, health systems, health plans, and life science organizations.

While the healthcare industry is in the infancy of a genomics revolution, its crucial for health systems, payers and providers to determine now how to infuse the rapid pace of discoveries into the healthcare ecosystem, said David Nixon, chief executive officer at InformedDNA. Jacqueline and Paul both have extensive executive leadership experience at major health plans and health systems. Each will no doubt make substantial contributions to InformedDNA, in their respective roles, as we help bring about a future in which genomics expertise will inform most healthcare decision-making, enabling true precision medicine to become a ubiquitous reality.

Dr. Kosecoff works in private equity to identify, select, mentor and manage health services and IT companies. She is managing partner at Moriah Partners, LLC, and senior advisor at Warburg Pincus. Previously, she served as a senior executive with UnitedHealth Group-PacifiCare where she was chief executive officer of OptumRx. Dr. Kosecoff was founder, president and chief operating officer of Protocare, and earlier, served as professor of Medicine and Public Health at the University of California, Los Angeles. She holds a B.A. from the University of California, Los Angeles, an M.S. in Applied Mathematics from Brown University, and a doctorate from the University of California, Los Angeles.

Said Dr. Kosecoff, Having been involved with InformedDNA as an advisor for the last year, Ive seen first-hand how the company brings a rare depth of genomics expertise to the healthcare industry, leading it to experience more than 50 percent annual growth in each of the last two years. I look forward to my new director role and increased interaction with the companys leaders as we enable additional healthcare companies to better understand the genomics space. This will facilitate better genetics-related decisions that result in more personalized care, improved outcomes, and lower costs.

Danao will focus on aligning sales, marketing and client management activities to deliver consistent and high-value contact to accelerate customer acquisition and retention. Prior to joining InformedDNA, he held senior leadership roles at several healthcare technology and service companies, including BlueCross BlueShield Association, AIM Specialty Health, and Healthcare Payment Specialists. Danao holds a B.B.A. from the University of Michigan and a Master of Health Services Administration from the University of Michigan School of Public Health.

This is a transformational time in the era of genetics-based medical care. InformedDNAs continued commitment to maintaining the highest level of genetics expertise and service excellence has already helped many leading U.S. healthcare organizations to decode the business of genetics, said Paul Danao, InformedDNAs new chief growth officer. Its with much enthusiasm that I join such a talented team of professionals to lead the companys sales and marketing initiatives for services that guide healthcare providers clinical decisions, help shape clinical trial processes, and enable insurers to craft evidence-based coverage policies for genetic tests.

About InformedDNA

InformedDNA is the authority on the appropriate use of genetic testing. It leverages the expertise of the largest, full-time staff of independent, board-certified genetics specialists in the U.S. to help ensure that health plans, hospitals, employers, clinicians and patients all have access to the highest quality genetic services. Key offerings include clinical genetic counseling, genetic testing utilization management, genetic testing payment integrity, and expert genetics clinical trial support. For more information: http://www.InformedDNA.com

Read more:
InformedDNA Recruits New Chief Growth Officer, Welcomes Industry Veteran to Board of Directors - Business Wire

WASHINGTON, Feb. 21, 2020 /PRNewswire/ --In a report released this morning, the Personalized Medicine Coalition (PMC) explains how 12 personalized treatments and seven diagnostics the U.S. Food and Drug Administration (FDA) approved or cleared in 2019 will improve patient care and make the health system more efficient by addressing root causes of rare diseases, expanding treatment options for cancer patients, and targeting therapies to responder populations. The approvals and clearance decisions expand the frontiers of the rapidly evolving field of personalized medicine for the benefit of patients and health systems.

Personalized Medicine at FDA: The Scope & Significance of Progress in 2019defines personalized medicine as a field "in which physicians use diagnostic tests to determine which medical treatments will work best for each patient or use medical interventions to alter molecular mechanisms, often genetic, that cause disease or influence a patient's response to certain treatments." The report classifies 11 new therapeutic molecular entities and one gene therapy as personalized treatments. Five of those treatments are the first to address root causes of devastating rare diseases. Four others provide new options for cancer patients, and two include FDA labeling that will help patients avoid debilitating and costly adverse side effects. The report also explains how seven newly cleared or approved diagnostics will help make the health care system more efficient by targeting treatments to only those patients who will benefit from them, sparing expenses and side effects for those who will not.

"Personalized Medicine at FDA: The Scope & Significance of Progress in 2019 reminds us that personalized medicine offers new hope to patients with devastating diseases as well as opportunities to avoid prescribing therapies that will be unsafe or ineffective for certain populations of patients," said Edward Abrahams, President, PMC.

In classifying 11 of the 44 (25 percent) new therapeutic molecular entities FDA approved last year as personalized medicines, this year's report marks the sixth straight year that personalized medicines have accounted for more than 20 percent of the agency's new drug approvals. These approvals have increased sharply since 2005, when personalized medicines accounted for just 5 percent of newly approved therapies.

About the Personalized Medicine Coalition:The Personalized Medicine Coalition (PMC), representing innovators, scientists, patients, providers and payers, promotes the understanding and adoption of personalized medicine concepts, services and products to benefit patients and the health system. For more information about PMC, visit http://www.personalizedmedicinecoalition.org.

PRESS CONTACT

Christopher J. WellsVice President, Public AffairsPersonalized Medicine Coalitioncwells@personalizedmedicinecoalition.org (202) 589-1755

View original content to download multimedia:http://www.prnewswire.com/news-releases/personalized-medicine-products-advanced-by-fda-in-2019-address-root-causes-of-rare-diseases-offer-expanded-options-for-cancer-patients-and-help-target-therapies-to-responders-pmc-report-shows-301009131.html

SOURCE Personalized Medicine Coalition

Read more here:
Personalized Medicine Products Advanced by FDA in 2019 Address Root Causes of Rare Diseases, Offer Expanded Options for Cancer Patients, and Help...

US researchers continue ongoing research into 3D printed pharmaceuticals, presenting their unique findings in Polymers for Extrusion-Based 3D Printing of Pharmaceuticals: A Holistic Materials-Process Perspective.

While many have predicted that the pharmaceutical industry was perched on the edge of a massive transformation due to the advantages offered by 3D printing, there are still many ongoing studies regarding suitable printers, materials, and critical issues such as the impacts of DIY drugs and more formalized manufacturing. In this study, the researchers examine both extrusion-based FDM 3D printing and pressure-assisted micro-syringe 3D printing as they compare them to more traditional processes, along with techniques, challenges, and consider the general direction of the industry overall.

Within the pharmaceutical industry today, 3D printing has made impacts in digital fabrication of drugs, implants, drug delivery systems, and more; however, the researchers point out the importance of such processes especially in creating personalized medications. Citing the success, and FDA approval, of epilepsy drug SPRITAM, the authors stress advantages in the trend toward patient-specific treatmentand specifically, medicine.

Current pharmaceutical manufacturing practices are not costeffective for personalized medicine, state the researchers. 3D printing pharmaceuticals are more suitable than current manufacturing practices for tailored solid dosages.

Although the first waves of pharmaceutical 3D printing began with inkjet printing, strides since then have been not only impressive, but fascinating to much of the public, including:

FDM and PAM printing processes have been most attractive to users due to accessibility and affordability, the potential for fabricating and tuning complex geometries, and more.

(a) The proportion of research articles published on different types of 3D printing processes in the last five years (20152019, total 202 articles); (b) The number of published scientific articles (research and review) in the period from 2015 to 2019 which reported the use of extrusionbased (fused deposition modeling (FDM) or pressureassisted microsyringe (PAM)) 3D printing (source: Scopus database and PubMed).

Choosing the right materials is critical to the success of 3D printing medications also, along with the capability for attaining FDA approval. As a highly suitable material, polymers may be used to print the following in relation to tablets and caplets:

Polymers multifaceted utilization in solid dosage drug delivery systems solidifies its importance in pharmaceutical 3D printing applications, state the researchers.

2dimensional (2D) schematic of the extrusionbased 3D printing process: (a) fuseddeposition modeling (FDM), (b) pressureassisted microsyringe (PAM).

And while they have reviewed studies from multiple other scientists, the authors here point out that while such guides are needed, no detailed discussion on how polymers should be selectedalong with other detailsexists.

Comparison of FDM and PAM 3D printing technologies

Processing is very similar via FDM or PAM, with the extra benefit of being more environmentally friendly, offering the ability for remote control of printing, and small batch, on-demand printing.

Comparison of different processing steps required for traditional direct compression (DC) tablet manufacturing vs. advanced manufacturing, 3D printing (FDM or PAM).

Typical polymers that can be used for 3D printing in pharmaceuticals include:

Summary of polymers based on (a) water solubility and drug release type, (b) their selection for either FDM or PAM 3D printing method.

Obviously, the pharmaceutical industry is highly regulated, with good reason, and the production of medications can be complex due to stringent requirements in production for the safety of the patient. In terms of 3D printing, however, a list of challenges still present themselves such as lack of predictability and consistency in quality of product due to issues like shrinkage or warping, problems with mechanical stability and other properties, and more.

Though a large-scale production of pharmaceuticals using 3D printing might be a long way from now, personalized medicine is possible inhouse for immediate use, conclude the researchers. Future work to enable drug product manufacture using FDM and PAM 3D printing technologies should include the suitability and characterization of polymers and other excipients amenable to processing.

Polymer materials and their properties, specifically their rheology should be investigated to allow a wider formulation and 3D printing design space. A better understanding of the rheological properties of APIpolymer mixtures and their measurement is necessary for the successful 3D printing of pharmaceuticals.

What do you think of this news? Let us know your thoughts! Join the discussion of this and other 3D printing topics at 3DPrintBoard.com.

Characterizations required for 3D printed structure, drug, and polymer (or other functional excipients, if necessary).

Here is the original post:
US Researchers Provide Holistic Perspective on Extrusion-Based 3D Printing of Personalized Medicine - 3DPrint.com

DUBLIN, Feb. 20, 2020 /PRNewswire/ -- The "Global Personalized Medicine Market Analysis 2019" report has been added to ResearchAndMarkets.com's offering.

The Global Personalized Medicine market is expected to reach $3.92 trillion by 2026, growing at a CAGR of 12.1% during the forecast period.

The efficient and advanced technology and higher prevalence of disease are driving the market growth. However, the higher cost of research and developments is hampering the market.

Based on the End-user, the hospital's segment is estimated to have a lucrative growth due to the lower cost personalized medicines availability in the hospitals. As the practice of personalized medicine becomes more widespread, hospitals will also experience the need to adapt. That does not mean every hospital and medical centre should try and drive the science, but they should be open to collaborations to facilitate such work.

The key vendors mentioned are Abbott Laboratories, Affymetrix Incorporated, Agendia N.V, Agilent Technologies, Inc, Amgen, Inc, Asuragen Incorporated, Bayer Healthcare Pharmaceuticals, Llc, Celera Diagnostics LLC, Celgene Corporation, Roche Diagnostics Corporation, Precision Biologics Incorporated, Siemens Healthcare Diagnostics, Inc, Sigma-Aldrich Corporation, Johnson & Johnson, Novartis AG, Decode Genetics Inc., Exact Science Corporation, Exagen Diagnostics Inc., GE Healthcare, and Genelex Corporation.

Key Questions Answered in the Report

Key Topics Covered

1 Market Synopsis

2 Research Outline

3 Market Dynamics3.1 Drivers3.2 Restraints

4 Market Environment

5 Global Personalized Medicine Market, By Product5.1 Introduction5.2 Diagnostics5.3 Personalized Medical Care5.4 Personalized Nutrition & Wellness5.5 Therapeutics

6 Global Personalized Medicine Market, By Technology6.1 Introduction6.2 Metabolomics6.3 Pharmacodynamics6.4 Pharmacogenetics6.5 Pharmacogenomics6.6 Pharmacokinetics6.7 Pharmacoproteomics6.8 Point-of-Care Testing6.9 Stem Cell Therapy

7 Global Personalized Medicine Market, By Therapeutic Area7.1 Introduction7.2 Autoimmune Diseases7.3 Blood Transfusion Safety7.4 Cancer Management7.5 Cardiovascular Diseases (CVD)7.6 Central Nervous System (CNS) Disorders7.7 Coagulation Therapy7.8 Diabetes7.9 Infectious Diseases7.10 Antiviral7.11 Neurology7.12 Psychiatry7.13 Oncology7.14 Immunology7.15 Respiratory

8 Global Personalized Medicine Market, By Distribution Channel8.1 Introduction8.2 Dietary Care Centers8.3 Hospital's Pharmacies8.4 Retail Pharmacies8.5 Other Distribution Channels

9 Global Personalized Medicine Market, By Application9.1 Introduction9.2 Biomarker Identification9.3 Clinical Research Applications9.4 Companion Diagnostics9.5 Health Informatics

10 Global Personalized Medicine Market, By End-user10.1 Introduction10.2 Academic Institutes10.3 Bio and Health Informatics Companies10.4 Clinical Care and Research Laboratories10.5 Contract Research Organizations10.6 Hospitals10.7 Molecular Diagnostic Laboratories and Testing Facilities10.8 Research Laboratories10.9 Service Providers10.10 Partner10.11 Venture Capitalists10.12 Other End-users

11 Global Personalized Medicine Market, By Geography11.1 North America11.2 Europe11.3 Asia-Pacific11.4 South America11.5 Middle East & Africa

12 Strategic Benchmarking

13 Vendors Landscape13.1 Abbott Laboratories13.2 Affymetrix Incorporated13.3 Agendia N.V13.4 Agilent Technologies Inc.13.5 Amgen Inc.13.6 Asuragen Incorporated13.7 Bayer Healthcare Pharmaceuticals, LLC13.8 Celera Diagnostics LLC13.9 Celgene Corporation13.10 Roche Diagnostics Corporation13.11 Precision Biologics Incorporated13.12 Siemens Healthcare Diagnostics Inc.13.13 Sigma-Aldrich Corporation13.14 Johnson & Johnson13.15 Novartis AG13.16 Decode Genetics Inc.13.17 Exact Science Corporation13.18 Exagen Diagnostics Inc.13.19 GE Healthcare13.20 Genelex Corporation

For more information about this report visit https://www.researchandmarkets.com/r/37rw80

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/personalized-medicine-market-worth-3-92-trillion-by-2026---insights-into-diagnostics-medical-care-nutrition--wellness-and-therapeutics-301008591.html

SOURCE Research and Markets

More here:
Personalized Medicine Market Worth $3.92 Trillion by 2026 - Insights Into Diagnostics, Medical Care, Nutrition & Wellness, and Therapeutics - P&T...

JUPITER, Fla., Feb. 20, 2020 /PRNewswire/ -- Jupiter Medical Center is pleased to announce an affiliation with Sylvester Comprehensive Cancer Center at the University of Miami Leonard M. Miller School of Medicine, providing access to groundbreaking cancer treatments to residents in Palm Beach County and the Treasure Coast. Part of the University of Miami Health System, Sylvester is South Florida's only National Cancer Institute (NCI)-designated cancer center.

The affiliation between Sylvester Comprehensive Cancer Center and Jupiter Medical Center will enable Jupiter cancer patients to have seamless access to Sylvester's highly specialized treatments, innovative therapies, world-renowned experts and clinical trials.

Patients with highly complex or rare cancers will benefit from the specialized expertise, leading-edge technology and clinical research available at NCI-designated cancer centers, such as Sylvester. Those treatments include bone marrow transplants, CAR T-cell immunotherapy, precision medicine approaches, cancer prevention, proton therapy coming later this year, and other new methods to preventing and treating cancer.

"Our affiliation allows patients to continue to receive world-class, personalized and comprehensive cancer care at Jupiter Medical Center, while making it easier for our patients to access the experts, specialized technology and scientific breakthroughs being made at Sylvester," said Dr. Amit Rastogi, president and chief executive officer of Jupiter Medical Center. "The relative proximity of Jupiter Medical Center and Sylvester will help support collaboration and cooperation between the medical teams at both institutions."

"We have a highly-qualified team of more than 300 cancer-focused physicians and researchers working together to deliver world class expertise in cancer prevention, innovative treatments and survivorship to patients," said Dr. Stephen D. Nimer, director of the Sylvester Comprehensive Cancer Center. "This affiliation allows Sylvester to work with a hospital that shares our mission to make advanced cancer care available to a broader community. We are very happy to have an opportunity to work with Jupiter Medical Center to provide pioneering treatments to more patients from Palm Beach County and the Treasure Coast."

Dedicated nurse navigators will facilitate communication and coordination of care between the medical teams at Sylvester Comprehensive Cancer Center and Jupiter Medical Center. The agreement also provides opportunities for cancer experts from both medical centers to collaborate on patient evaluation, diagnosis, and treatment, sharing best practices to determine the best treatment plans for all types of cancer.

Jupiter Medical Center is home to the new Anderson Family Cancer Institute, a 55,000-square-foot, state-of-the-art cancer center opening in March 2020. Accredited by the American College of Radiology, the Commission on Cancer and the National Accreditation Program for Breast Centers, Jupiter Medical Center offers full spectrum of cancer care, including advanced diagnostics, personalized treatments provided by a multidisciplinary team of clinicians, support services for family and caregivers and survivorship programs.

Sylvester Comprehensive Cancer Center is one of only 71 NCI-designed centers nationwide. This designation recognizes cancer centers that meet rigorous standards for multi-disciplinary care and state-of-the-art research focused on developing new approaches to treating and curing cancer.

About Sylvester Comprehensive Cancer Center

Sylvester Comprehensive Cancer Center, part of UHealth - University of Miami Health System and the University of Miami Miller School of Medicine, is the only cancer center in South Florida designated by the National Cancer Institute. NCI designation recognizes that Sylvester has met the most rigorous standards for cancer research, beginning in our laboratories, extending to patient care, and meeting specific needs in our community. Sylvester is known as South Florida's leader in patient-focused cancer research and care, offering the only Phase 1 Clinical Trials program the first step in evaluating how patients respond to the latest investigational treatments. NCI designation further expands Sylvester's ability to provide access to novel therapies through more clinical trials and collaboration with other designated centers. Equipped with a highly qualified team of more than 300 cancer-focused physicians and researchers working together, Sylvester discovers, develops, and delivers more precision cancer care. To serve current and future patients, Sylvester has a network of conveniently located outpatient treatment facilities throughout South Florida.

About Jupiter Medical Center

Ranked #1 for quality, patient safety and patient satisfaction, Jupiter Medical Center is the leading destination for world-class health care in Palm Beach County and the greater Treasure Coast. In 2019, the Leapfrog Group named Jupiter Medical Center a "Top Hospital," a distinction earned by only 6 percent of hospitals nationwide. Jupiter Medical Center is also the only hospital in Palm Beach, Martin, St. Lucie and Indian River counties to receive a 4-star quality and safety rating from the Centers for Medicare & Medicaid Services (CMS). Outstanding physicians, state-of-the-art facilities, innovative techniques and a commitment to serving the community enable Jupiter Medical Center to meet a broad range of patient needs. The region's only independent, not-for-profit hospital, Jupiter Medical Center offers specialty concentrations in orthopedics and spine care; cancer care and oncology; cardiac and vascular care; neuroscience and stroke care; women's and children's services; urgent care; and other key areas. For more information on Jupiter Medical Center, please call (561) 263-2200 or visit jupitermed.com.

View original content to download multimedia:http://www.prnewswire.com/news-releases/jupiter-medical-center-and-sylvester-comprehensive-cancer-center-part-of-the-university-of-miami-health-system-enter-affiliation-to-advance-cancer-treatment-in-palm-beach-county-301008737.html

SOURCE Jupiter Medical Center

Read the rest here:
Jupiter Medical Center and Sylvester Comprehensive Cancer Center, part of the University of Miami Health System, Enter Affiliation to Advance Cancer...

CHICAGO, Feb. 21, 2020 /PRNewswire/ -- According to the new market research report "Single-cell Analysis Marketby Cell Type (Human, Animal, Microbial), Product (Consumables, Instruments), Technique (Flow Cytometry, NGS, PCR, Mass Spectrometry, Microscopy), Application (Research, Medical Application), End User - Global Forecasts to 2025", published by MarketsandMarkets, the Single-cell Analysis Marketis projected to reach USD 5.6 billion by 2025 from USD 2.1 billion in 2019, at a CAGR of 17.8% during the forecast period.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=171955254

The growth in this market is driven by technological advancements in single-cell analysis products, increasing government funding for cell-based research, growing biotechnology and biopharmaceutical industries, wide applications of single-cell analysis in cancer research, growing focus on personalized medicine, and the increasing incidence and prevalence of chronic and infectious diseases. However, the high cost of single-cell analysis products is expected to restrain the growth of this market to a certain extent during the forecast period.

The research applications segment accounted for the largest share of the market, by application, in 2018

Based on application, the Single-cell Analysis Market is segmented into research (cancer, immunology, neurology, stem cell, and other research applications) and medical applications (noninvasive prenatal diagnosis, in vitro fertilization, and circulating tumor cell detection). The research applications segment accounted for the largest share of the market in 2018. Increasing government initiatives in stem cell research and the wide usage of single-cell analysis in cancer research are the major factors driving the growth of the research applications segment.

Browsein-depth TOC on"Single-cell Analysis Market"

225 Tables 50 Figures252 Pages

The flow cytometry segment accounted for the largest market share in 2018

Based on technique, the market is segmented into flow cytometry, NGS, PCR, microscopy, mass spectrometry, and other techniques. The flow cytometry segment accounted for the largest market share in 2018. The large share of this segment is attributed to the wide usage of flow cytometry in detecting and measuring the physical and chemical characteristics of a population of cells or particles. However, the NGS segment is projected to register the highest growth rate during the forecast period. The high growth of the NGS segment is driven by the increasing application of single-cell analysis products in drug discovery for cancer and other chronic diseases.

Get 10% Customization on this Research Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=171955254

North America dominates the Single-cell Analysis Market

The global market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2018, North America accounted for the largest share of the market. The growth in this market can be attributed to the increasing drug development activities in the pharmaceutical and biotechnology industries, rising prevalence of chronic and infectious diseases, and an increase in stem cell research activities.

Prominent players in the Single-cell Analysis Market include Becton, Dickinson and Company (US), Danaher Corporation (US), Merck Millipore (US), QIAGEN (Netherlands), Thermo Fisher Scientific (US), General Electric Company (US), 10x Genomics (US), Promega Corporation (US), Illumina (US), Bio-Rad Laboratories (US), Fluidigm Corporation (US), Agilent Technologies (US), NanoString Technologies (US), Tecan Group (Switzerland), Sartorius AG (Germany), Luminex Corporation (US), Takara Bio (Japan), Fluxion Biosciences (US), Menarini Silicon Biosystems (Italy), and LumaCyte (US).

Browse Adjacent Markets: Biotechnology Market ResearchReports & Consulting Get Special Pricing on Bundle Reports:

https://www.marketsandmarkets.com/RequestBundleReport.asp?id=171955254

Browse Related Reports:

Cell Counting Marketby Product (Instruments (Spectrophotometer, Cell Counter, Hemocytometer, Flow Cytometer, Hematology Analyzer), Consumables (Reagent, Assay Kits, Microplate)), End User (Pharmaceutical, Hospital, Research) - Global Forecast to 2023

Cell Isolation/Cell Separation Marketby Product (Reagents, Beads, Centrifuge), Cell Type (Human, Animal), Cell Source (Bone Marrow, Adipose), Technique (Filtration), Application (Cancer), End User (Hospitals, Biotechnology) - Global Forecast to 2024

About MarketsandMarkets

MarketsandMarkets provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:Mr. Sanjay GuptaMarketsandMarkets INC.630 Dundee RoadSuite 430Northbrook, IL 60062USA: +1-888-600-6441Email: sales@marketsandmarkets.com Research Insight: https://www.marketsandmarkets.com/ResearchInsight/single-cell-analysis-market.asp Visit Our Website:https://www.marketsandmarkets.com Content Source:https://www.marketsandmarkets.com/PressReleases/single-cell-analysis.asp

SOURCE MarketsandMarkets

Read the rest here:
Single-cell Analysis Market Worth $5.6 Billion by 2025 - Exclusive Report by MarketsandMarkets - PRNewswire

Bringing new medicines to patients struggling with serious illness is the driving force behind drug discovery and development. Originating as small molecules, drugs have shifted to large molecule therapies and will continue to shift as precision medicine is adopted. In spite of these different types of drugs, the development time to create them has not changed dramatically. It still takes 10 to 15 years to bring a drug to market. For this reason, there is tremendous interest when it comes to finding ways to develop drugs with higher throughput methods. This article highlights advances in three technology areas that show great promise to speed the drug discovery and development process.Automation and roboticsThe need for automation and robotics is not a new topic in drug discovery but an area where great progress has been and continues to be made. Automation is essential to implementing high-throughput strategies. What started out as a solution to achieve higher throughput has extra benefits. An automated process provides better data quality due to process consistency. Human error is minimized, and the presence of an audit trail allows traceability if questions arise. Automation also provides walk away freedom for the scientist to pursue other tasks.

To witness an automated set up, one may find that each automation step may not be fast in and of itself. But consider the shift away from an 8-hour employee workday to one of continuous 24-hour operation. Screening projects are now reduced by at least a factor of 3, thus yielding higher throughput.

Automation can be categorized into three general modes defined as (1) batch, (2) semi-automated, and (3) integrated. The three modes range from limited to extensive on key automation criteria which include things like flexibility, walk away capabilities, number and complexity of tasks. Batch mode, for example still requires a scientist to load stacks of plates that then are subjected to a limited step in the process. Integrated automation, the most sophisticated, is capable of carrying out multiple scheduled steps facilitated by a robotic mover. This allows unmanned operation for extended periods providing walk away or overnight convenience.1An important consideration in any automated solution is the skill requirement of the operator. More sophisticated systems will require automation programming skills often leveraging automation engineers. Specialized training from the equipment vendor may also be required. Batch automation can often be accomplished with little specialized training. Compared to ten years ago, automation today has evolved and become more democratized. This continued trend will reduce the need for specialized training in the future with more turn-key and intuitive solutions becoming commercially available.

David Ebner, Principal investigator at the Target Discovery Institute in Oxford, UK explains: There are two key limiting factors for any group trying to do high-throughput screening today. The first is the expertise to translate a benchtop assay to a high-throughput platform and the second factor is the expense. Centralized core facilities are one way to address the expense factor. And as automation becomes more turn-key, the need for specialized engineers is reduced, allowing future resources to be more research scientist driven.

The discovery and development of small molecules and antibodies targeting T cell function, as well as T cell-based cell therapies and cell manufacturing, require assays to rapidly and reliably profile T cell activation and cell health. In this app note, discover how phenotypic screening addresses these needs, using a single assay to provide rapid, optimized monitoring of cell proliferation, activation markers and cytokines.

Microfluidic technology, a more extreme form of miniaturization, addresses some of these known fluid handling challenges.4 Microfluidic chips provide the benefits of reduced volumes while replacing liquid handling mechanics with channels connected to liquid reservoirs. In some cases, the device has integrated tools such as electrodes built-in and can combine multiple operational steps. 5Microfluidic devices are also able to isolate single cells, which can be further cultured on the chip. This ability removes cellular heterogeneity on cancer cell populations as an example. Traditional drug screening methods see response information from an average of all cells. The microfluidic solution allows analysis of a single cell's antidrug response.4 In addition to this cell-on-chip model, recent advances have led to tissue-on-chip and organ-on-chip models which are still early in development. These kind of chip models may someday provide a powerful alternative to animal models.6 Because they are early in development, they are not high- throughput solutions today. But they show great promise to speed determination of drug activity, optimal combinatorial drug screening and toxicity testing in the future.4Artificial intelligenceApplied to drug discovery, artificial intelligence (AI) has been used in medicinal chemistry for designing compounds since the 1960s. 7 Machine-learning tools like quantitative structure-activity relationship (QSAR) modeling have identified potential target molecules from millions of candidate compounds. 8 Today, AI has expanded its application in drug discovery to a range of tasks from robotics control to image analysis and logistics. AI has also been applied throughout the drug discovery process from target selection, hit identification, lead optimization through to preclinical studies and clinical trials. 7, 8Dr Mohammad HamediRad and colleagues at the University of Illinois explain that with new uses of AI, "the role of researcher changes from drivers of the experiments to supervisors of the system." AI, integrated with robotic systems enables automation of the design, build, test, and learn (DBTL) cycle. This results in a platform that designs experiments, executes them, analyzes the data then optimizes and executes subsequent experiments iteratively. This closed loop discovery reduces the total number of experiments and generates the best possible optimization. The concept was demonstrated by HamediRad and colleagues in 2019. Their fully-automated platform evaluated less than 1% of possible variants and outperformed traditional screening methods by 77%.9AI platforms can cut down the development time from lead molecule to a candidate by more than half. AI predicted molecules are more likely to be correct and allow a focused effort. Time isnt wasted testing irrelevant molecules which would have been worked on otherwise and make up 90% of the molecules tested by traditional methods.10 Currently, AI can help find novel compounds which are more potent and selective using high quality screening data sets much faster and at less expense than screening alone, explains Ebner.

Personalized or precision medicine is another area where AI plays an important role. Precision medicines are a growing proportion of drugs in the industry pipeline. 11 Extensive collections of human samples (diseased and healthy) are required for biomarker identification in developing a personalized medicine. 12 Typically, all samples are sequenced using next-generation sequencing which generates massive amounts of data. AI methods of deep-learning make analysis of these big data sets possible. 8Automation Journey Guide: How To Automate Simple to Complex Workflows For Achieving Results Beyond High-throughput

Laboratory automation is playing a key role in advancing scientific research, from pharmaceutical development to diagnostics. Whether it is to automate a simple or sophisticated workflow, automation is now used in labs throughout the world to increase their capacity and throughput. In this eBook, discover a detailed guide to introducing automation to your lab.

Read this article:
High-throughput Technologies in Drug Discovery - Technology Networks

Global Precision Medicine Marketto grow with a substantial CAGR in the forecast period of 2019-2026. Growing prevalence of cancer worldwide and accelerating demand of novel therapies to prevent of cancer related disorders are the key factors for lucrative growth of market

Key Market Players:

Few of the major competitors currently working in the global precision medicine market are Neon Therapeutics, Moderna, Inc, Merck & Co., Inc, Bayer AG, PERSONALIS INC, GENOCEA BIOSCIENCES, INC., F. Hoffmann-La Roche Ltd, CureVac AG, CELLDEX THERAPEUTICS, BIONTECH SE, Advaxis, Inc, GlaxoSmithKline plc, Bioven International Sdn Bhd, Agenus Inc., Immatics Biotechnologies GmbH, Immunovative Therapies, Bristol-Myers Squibb Company, Gritstone Oncology, NantKwest, Inc among others.

Download Free PDF Sample Copy of[emailprotected]http://databridgemarketresearch.com/request-a-sample/?dbmr=global-precision-medicine-market

Global Precision Medicine MarketBy Application (Diagnostics, Therapeutics and Others), Technologies (Pharmacogenomics, Point-of-Care Testing, Stem Cell Therapy, Pharmacoproteomics and Others), Indication (Oncology, Central Nervous System (CNS) Disorders, Immunology Disorders, Respiratory Disorders, Others), Drugs (Alectinib, Osimertinib, Mepolizumab,Aripiprazole lauroxil and Others), Route of Administration (Oral,Injectable), End- Users (Hospitals, Homecare, Specialty Clinics, Others), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) Industry Trends and Forecast to 2026

Competitive Analysis:

The precision medicine market is highly fragmented and is based on new product launches and clinical results of products. Hence the major players have used various strategies such as new product launches, clinical trials, market initiatives, high expense on research and development, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of mass spectrometry market for global, Europe, North America, Asia Pacific and South America.

Market Drivers

Market Restraints

Talk to The Author of Report @http://databridgemarketresearch.com/speak-to-analyst/?dbmr=global-precision-medicine-market

Market Definition:

Precision medicines is also known as personalized medicines is an innovative approach to the patient care for disease treatment, diagnosis and prevention base on the persons individual genes. It allows doctors or physicians to select treatment option based on the patients genetic understanding of their disease.

According to the data published in PerMedCoalition, it was estimated that the USFDA has approved 25 novels personalized medicines in the year of 2018. These growing approvals annually by the regulatory authorities and rise in oncology and CNS disorders worldwide are the key factors for market growth.

Grab Your Report at an Impressive 30% Discount! Please click[emailprotected]https://www.databridgemarketresearch.com/request-a-discount/global-precision-medicine-market

Key Developments in the Market:

Competitive Analysis:

Global precision medicine market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of global precision medicine market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Market Segmentation:

By technology:-big data analytics, bioinformatics, gene sequencing, drug discovery, companion diagnostics, and others.

By application:- oncology, hematology, infectious diseases, cardiology, neurology, endocrinology, pulmonary diseases, ophthalmology, metabolic diseases, pharmagenomics, and others.

On the basis of end-users:- pharmaceuticals, biotechnology, diagnostic companies, laboratories, and healthcare it specialist.

On the basis of geography:- North America & South America, Europe, Asia-Pacific, and Middle East & Africa. U.S., Canada, Germany, France, U.K., Netherlands, Switzerland, Turkey, Russia, China, India, South Korea, Japan, Australia, Singapore, Saudi Arabia, South Africa, and Brazil among others.

In 2017, North America is expected to dominate the market.

About Data Bridge Market Research:

Data Bridge Market Researchset forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:[emailprotected]

See original here:
PRECISION MEDICINE MARKET 2020: INDUSTRY ANALYSIS AND DETAILED PROFILES OF TOP INDUSTRY PLAYERS ARE NEON THERAPEUTICS, MODERNA, INC, MERCK & CO.,...

An international team of scientists, spearheaded by a 20 million ($25.9 million) award from Cancer Research UK, has developed the most detailed maps of breast cancer available, which map breast tumor samples to a resolution smaller than a single cell.

The maps, published in Nature Cancer this week, detail the intricacies and complexity of the cancer landscapecomprising cancer cells, immune cells, and connective tissueand how it varies both between, and within, tumors depending on their unique genetic makeup.

At the moment, doctors only look for a few key markers to understand what type of breast cancer someone has, said Dr. Raza Ali, junior group leader at the Cancer Research UK Cambridge Institute, and the studys lead author. But as we enter an era of personalized medicine, the more information we have about a patients tumor, the more targeted and effective we can make their treatment.

In the future, the hope is that such a map could provide clinicians with a wealth of information specific to each patients tumor at the time of diagnosis, thus providing an opportunity to match patients with the most appropriate therapy. The information would also be used to analyze tumor during a patients treatment to more clearly see how a patient is responding to their therapy and to adjust the treatment regimen based this.

In the study, the international research teams from Cancer Research UK Cambridge Institute, University of Cambridge; the University of Zrich, Switzerland; and the British Columbia Cancer Research Centre, Canada, studied 483 different tumor samples collected during the Cancer Research UK funded METABRIC study, a project that has already significantly improved the understanding of the disease by revealing that there are at least 11 different subtypes of breast cancer.

The team looked within the samples for the presence of 37 key proteins, indicative of the characteristics and behavior of cancer cells. Using a technique called imaging mass cytometry, they produced detailed images, which revealed precisely how each of the 37 proteins were distributed across the tumour.

The researchers then combined this information with genetic data from each patients sample to further enhance the image resolution. This is the first time imaging mass cytometry has been paired with genomic data.

These tumor blueprints expose the distribution of different types of cells, their individual characteristics and the interactions between them.By matching these pictures of tumors to clinical information from each patient, the team also found the technique could be used to predict how someones cancer might progress and respond to different treatments.

Professor Carlos Caldas, from the Cancer Research UK Cambridge Institute and co-author of the study said: Weve shown that the effects of mutations in cancer are far more wide-ranging than first thought.They affect how cancer cells interact with their neighbours and other types of cell, influencing the entire structure of the tumour.

The research was funded by Cancer Research UKs Grand Challenge initiative. By providing international, multidisciplinary teams with 20 million grants, this initiative aims to solve the biggest challenges in cancer.

This team is making incredible advances, helping us to peer into a future when breast cancer treatments are truly personalized, said Dr. David Scott, director of Grand Challenge at Cancer Research UK. Theres still a long way to go before this technology reaches patients, but with further research and clinical trials, we hope to unlock its powerful potential.

Originally posted here:
Detailed Map of Breast Cancer Reveals the Effects of Mutations on the Tumor Landscape - Clinical OMICs News

Xtalks Life Science Webinars

TORONTO (PRWEB) February 21, 2020

Pharmaceutical manufacturers are under increasing pressure to fast-track technological innovation to improve their manufacturing operations in order to adapt to new approaches like Industry 4.0 and continuous manufacturing, combat the growing and intense competition and keep up with the increasing demand for personalized medicine and therapies. But with an industry with the worlds tightest regulations and complex value chains, what are the correct steps to reaching operational intelligence in a GxP compliant manner with end-to-end data integrity?

Attend this webinar to learn:

Join speakers from Bigfinite including CEO Pep Gubau and Product Owner Christina Fernandez in a live webinar on Monday, March 9, 2020 at 1pm EDT to learn about how you can gain better knowledge of your operational realities and why you should consider GxP compliance today rather than delaying work to establish these regulatory systems now.

For more information or to register for this event, visit Why Companies Need GxP for their Digital Transformation Projects Now.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

Read the rest here:
Why Companies Need GxP for their Digital Transformation Projects Now, Upcoming Webinar Hosted by Xtalks - PR Web

For women with advanced cases of cervical cancer, radiation therapy is generally the only curative treatment. The treatment of cervical cancer is unique, in that, brachytherapy, a form of radiation treatment where radioactive isotopes are placed within or near tumors, is a necessary component.

Dr. Michelle Ludwig, a radiation oncologist at the Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine, and Dr. Alexander Hanania, fourth-year resident physician in radiation oncology at Baylor, both see patients at Harris Health Systems Attwell Radiation Therapy Center at Smith Clinic. They are researching a way to make brachytherapy more efficient and less toxic for patients with cervical cancer.

Cervical cancer is a disease more common in medically underserved patients who have less access to screening and vaccination, Ludwig said. We are excited to work to bring access to personalized medicine in the form of a customizable device to the medically underserved patients in Harris County, as we have one of the highest volume centers in the country for this patient population.

Reserved solely for the most technical and challenging of cases, a procedure called interstitial brachytherapy allows doctors to deliver higher doses of radiation internally and directly to the tumor.

Interstitial brachytherapy is generally only needed for patients with large advanced tumors, or when there is another reason such as anatomical challenges or disease recurrence, Hanania said. In certain areas where we treat the uninsured population, more often than not, were seeing locally advanced disease, which often requires interstitial brachytherapy.

Historically, the procedure involves suturing a grid template to the body, then inserting a series of needles through the template holes and into the tissue involved with and surrounding the tumor. Radioactive isotopes are run through the needles to deliver the radiation and kill the tumor.

The procedure is highly effective in controlling and often curing cervical cancer that has not spread to other parts of the body, but it can also be damaging to the tissues and organs surrounding the cervix. According to Hanania, new devices on the market allow for more precise treatment but most are too expensive for most hospitals.

Last fall, Hanania visited Rice University with the hopes of finding an affordable solution. He presented the problem at an engineering design fair where students met with potential collaborators in a variety of industries. He met a group of five undergraduate students seniors Elisa Arango, Susannah Dittmar, Krithika Kumar and Sanika Rane and junior Lauren Payne all interested in addressing a global health issue.

We know that the women affected by cervical cancer have less access to healthcare, Dittmar said. These women shouldnt have to go through this painful, extensive treatment just because of their financial situation. We wanted to find a way to make the procedure better.

The group, which calls themselves Team At Your Cervix, got to work designing a new obturator that could be built with a 3D printer at Rices Oshmann Engineering Design Kitchen. After months of research and collaboration with Ludwig and Hanania, they now have a prototype called the Universally Friendly Obturator, or UFO.

Our goal was to reduce the number of transcutaneous needles, Dittmar said. The way were going to do that is by bringing them into the obturator so theyre going through the vaginal canal and not through the tissue.

The UFO is also wider than a traditional obturator and has a flexible head so the needles can better reach the cervix without disturbing the surrounding tissue.

Our goal was for it to be 3D printed so it can be an open sourced file, Payne said. Because were a global health project, it has to be low cost. The idea is that anyone in the world can access the file and print it.

In the coming months, the group will continue to develop and test new prototypes. They have designed simulations to see how the device would hold up in a real procedure

I think this device could decrease the morbidity of the implant. If its effective, it will not only shorten the amount of time that were in the operating room, it will also decrease the amount of trauma to the body, Hanania said. Every needle you put in increases the risk of trauma to other nearby parts of the body. This device would work with existing technology to make the therapy more targeted, and therefore less toxic.

The group will present their final prototype at the Rice Engineering Design Showcase at Tudor Fieldhouse on Thursday, April 16. After graduation, the team hopes another group of seniors will continue their work.

Dr. Hanania and Dr. Ludwig came to us with an actual problem that they face, said Rane, who will be attending Baylors School of Medicine in the fall. Our prototype can have an immense effect here in Houston and across the globe.

-By Molly Chiu

See the rest here:
Doctors team up with students to improve cervical cancer treatment - Baylor College of Medicine News

Are you in the United Kingdom and looking for a job in the life sciences? Or, are you planning on having a career in the life sciences? If so, then, youll be happy to know that there are an expected 133,000 jobs to be added to the sector over the next 10 years.

A new report called the Life Sciences 2030 Skills Strategy published in collaboration with theAssociation of the British Pharmaceutical Industry and the U.K.s Office for Life Sciences, forecasts the addition of 133,000 life science jobs by 2030. The jobs will range across the sector and include biopharma, medical devices and other areas of the industry. Specifically, the report predicts the addition of 43,000 jobs in biopharma, about 90,000 jobs in medtech and another 55,000 jobs to replace retirees across the sector.

The forecast does get a little more specific for the types of positions that will be needed in the U.K. over the next 10 years. For example, the report suggests that pharma research and development will require about 19,300 positions, while manufacturing roles in pharma will grow by about 6,400 jobs. While those are strong numbers, the report suggests that the medical device industry will see even greater growth.

The report projects 8,000 new jobs in medtech research and development and 46,500 jobs in medtech manufacturing.

For the other positions, the report suggests that by 2030, there will be an increase of 52,400 service and supply positions in the industry.

Alex Felthouse, managing director, Eisai Manufacturing and chairman of the Science Industries Partner Futures Group, a participant in the survey, said the strategy guide lays out the recommendations to take skills forward out to 2030 in support of the growing life sciences industry

To meet the demand that we have for the future we need to ensure that our industry is attractive to those who are considering joining the sector. We need to make them aware of all of the fantastic opportunities there are across a diverse and exciting range of activities from research and development through to medicines manufacturing. We also need toensure we have parity of esteem between different educational routes whether it be traditional academic routes, apprenticeships, vocational studies or ongoing continued professional development.

In order to capture some of these positions, the Life Sciences 2030 Skills Strategy outlines some of the key skills that will be needed by applicants. The skill sets include, as could be expected, proficiency in computers, as well as statistical literacy. The skills outlined are broad, but with the increasing reliance on machine learning and artificial intelligence in the pharmaceutical industry, that should provide more direction for potential applicants. The report notes that there is an accelerating convergence between life sciences, computer science, mathematics, statistics, engineering and chemistry in the fields of diagnostics, personalized medicine and data science.

There are also a number of soft skills that will be of benefit for future applicants. According to the survey, those kinds of skills will involve effective communication, leadership skills, sales and marketing abilities, as well as translational commercialization skills.

With the projected growth of jobs over the next 10 years, Nadhim Zahawim, business and industry minister for the U.K., said the government of the United Kingdoms hope is that the country will become a science superpower. By creating cutting-edge jobs in the life sciences industry, that will help the U.K. make progress in areas such as early medical diagnosis and manufacturing, Zahawim said in a statement. By providing a pathway for the growth, Zahawim said this will help level up every part of the UK with new opportunities.

In order to meet the demands, the government made several recommendations, including the implementation of an action plan from key stakeholders to oversee the growth of the industry. This action plan is aimed at encouraging and incentivizing the take-up of apprenticeships programs in all parts of the sector in order to establish parity of esteem with academic routes. Additionally, the action plan calls for supporting the transfer and exchange of a global workforce. The action plans have yet to be finalized, but when they are, the government said it will establish certain as-yet unnamed milestones and targets.

The government also points out that it will need to promote science, technology, engineering and mathematics programs to boost the increase of potential applicants, and also create a positive landscape that will attract and retain globally mobile talent. The strategy also notes that encouraging some academic researchers to shift into industry will also be key.

See original here:
Life Sciences Jobs Expected to Grow by 133,000 Over Next 10 Years in the UK - BioSpace

AI is rocking medical diagnosis with its potential to incite drastic improvements to hospital processes. AI can process images and patient health records with more accuracy and expediency than humans are capable of, lessening physician workload, reducing misdiagnosis, and empowering clinical staff to provide more value.

While early moving hospitals are already extracting value from AI in medical diagnosis, most US hospitals are at the very early stage of the AI transformation curve - and they risk falling behind if they don't move now.

In this report, Business Insider Intelligence examines the value of AI applications in three high-value areas of medical diagnosis - imaging, clinical decision support, and personalized medicine - to illustrate how the tech can drastically improve patient outcomes, lower costs, and increase productivity.

We look at US health systems that have effectively applied AI in these use cases to illustrate where and how providers should implement AI. Finally, we examine how a leading US health system validates AI partners and internally organizes its AI strategy to offer provider organizations a template for AI innovation.

The companies mentioned in this report are: Aidoc, Allscripts, Amazon, Arterys, Boston Gene, Cabell Huntington Hospital, Cerner, Cleveland Clinic, Epic, Geisinger Health System, Google, HCA Healthcare, IBM, iCAD, IDx, Intermountain Healthcare, Johns Hopkins, Meditech, Microsoft, Mount Sinai, NorthShore University HealthSystem, Oak Street Health, Stanford University, Tempus, UCI Health System, Unanimous AI, Verily, Viz.ai, and Yale New Haven Hospital.

Here are some of the key takeaways from the report:

In full, the report:

Want to learn more about the fast-moving world of digital health? Here's how to get access:

Read more:
AI IN MEDICAL DIAGNOSIS: How top US health systems are reacting to the disruptive force of AI by revolutionizi - Business Insider India

North American Prostate Cancer Diagnostics and Therapeutics Market Size, Share & Trends Analysis Report by Diagnostic Technique (Prostate-Specific Antigen Test, Digital Rectal Examination, Prostate Biopsy, Imaging Techniques) by Therapeutics (Hormonal Therapy, Chemotherapy, Immunotherapy, Radiation Therapy, Targeted Therapy, Surgery) and Forecast 2019-2025

North American prostate cancer diagnostics and therapeutics market is expected to grow at a CAGR of 10.4% during the forecast period. The major factors for the growth of the market include the high prevalence of prostate cancer in the region which raises the demand for efficient diagnostics and therapies for the treatment of cancer.

As per World Health Organization, in the North America, prostate cancer is the most prevalent cancer among men. Around 234,000 new cases of prostate cancer has been registered in 2018 in the region.

Additionally, in 2018, around 18.5% of the total cases of cancer are related to prostate cancer in the US. Moreover, the adoption of innovative technologies for the diagnosis of prostate cancer such as biomarkers and the adoption of personalized medicine for treatment is expected to fuel the market.

Report: http://www.omrglobal.com/requesttic-market

North American prostate cancer diagnostic market is divided on the basis of diagnostic technique and therapeutics. By diagnostic technique, the market is segmented into prostate-specific antigen test, digital rectal examination, prostate biopsy, imaging techniques.

Prostate biopsy is expected to hold a major market share during the forecast period. By therapeutics, the market is segmented into hormonal therapy, chemotherapy, immunotherapy, radiation therapy, targeted therapy, surgery.

During the forecast period, chemotherapy is expected to have a major market share in the region. Geographically, the market is divided into the US and Canada.

The US is expected to hold the major major market share during the forecast period.

Report: http://www.omrglobal.com/industrtic-market

North American Prostate Cancer Market Segmentation

By Diagnostic Techniques

By Therapeutics

Regional Analysis

Company Profiles

Report: http://www.omrglobal.com/report-tic-market

This email address is being protected from spambots. You need JavaScript enabled to view it.

Visit link:
North American Prostate Cancer Market scrutinized in the new analysis - WhaTech Technology and Markets News

Dublin, Feb. 12, 2020 (GLOBE NEWSWIRE) -- The "In-Vitro Toxicology/Toxicity Testing Market by Product & Services, Toxicity Endpoint & Test (Carcinogenicity, Dermal Toxicity), Technology (Cell-based, HTS), Method (Cellular Assays), Industry (Pharmaceutical, Cosmetics), Region-Global Forecast to 2024" report has been added to ResearchAndMarkets.com's offering.

The In-Vitro Toxicology Testing Market is Expected to Reach USD 12.7 Billion by 2024 from an Estimated USD 8.1 Billion in 2019, at a CAGR of 9.3%.

The opposition to animal testing, technological advancements, and increasing R&D expenditure to detect toxicity at an early stage during drug development are the primary growth factors for this industry.

The increasing focus of the pharmaceutical and cosmetics industries on using in-vitro methods for product testing along with the improvement in silico methods for predictive toxicology studies are expected to offer significant growth opportunities for players in this market. However, the dearth of skilled professionals is a substantial market challenge.

The software segment is expected to grow at the highest rate during the forecast period.

Based on the product & service, the in-vitro toxicology testing market is segmented into consumables, assays, equipment, software, and services. The software segment is projected to witness the highest growth in the in-vitro toxicology testing market during the forecast period.

Growth in this segment is driven mostly by the rising number of new technologies to develop in-vitro signatures and computational models capable of predicting in vivo responses. Also, the increasing use of the latest software in the industry and the academia to predict toxicity by comparing the data of new substances with other structurally or biologically similar compounds, are expected to drive the growth of this segment.

The ADME segment is expected to account for the largest market share in 2018.

Based on toxicity endpoints & tests undertaken across all industries, the in-vitro toxicity testing market is segmented into ADME; skin irritation, corrosion, and sensitization; genotoxicity; cytotoxicity; ocular toxicity; organ toxicity; phototoxicity; dermal toxicity; and other endpoints & tests. The ADME segment accounted for the largest share of the in-vitro toxicity testing market in 2018. This can be attributed to the high adoption during the drug development process with the advantage of producing highly reproducible & accurate data.

Toxicogenomics is expected to grow at the highest rate during the forecast period.

The toxicogenomics segment is expected to grow at the highest CAGR during the forecast period, primarily due to the technological advancements taking place in the field of proteomics and genomics. Also, the improvements in proteomic technologies are enhancing the study of gene & protein activity during toxicity analysis. Technological advancements taking place in the field of proteomics and genomics will further drive the growth of this segment in the coming years.

Europe is expected to hold the largest share for players operating in the in-vitro toxicology testing market.

Europe accounted for the largest share of the in-vitro toxicology testing market in 2018. Factors such as high adoption of in-vitro toxicology testing assays and services in the cosmetics and chemical industries after the ban on animal testing in the region are among the few factors expected to contribute to the growth of this market.

Story continues

Market Dynamics

Market Drivers

Opposition to Animal Testing

Technological Advancements

R&D Toward Early Stage Toxicity Detection

Market Restraints

Reluctance of Regulatory Authorities to Consider Alternative Methods for Proving Safety and Efficacy

Failure to Establish the Intricacies of in Vivo Conditions, In Vitro

Lack of In Vitro Models to Study Complex Endpoints

Market Opportunities

Market Challenges

Company Profiles

Bio-Rad Laboratories, Inc.

Bioivt

Catalent, Inc.

Charles River Laboratories International, Inc.

Covance, Inc.

Creative Bioarray

Creative Biolabs

Cyprotex PLC

Eurofins Scientific SE

GE Healthcare

Gentronix Limited

GVK Biosciences Private Limited

Insphero

MB Research Laboratories

Merck KGaA

Promega Corporation

Qiagen N.V.

SGS S.A.

Shanghai Medicilon Inc.

Thermo Fisher Scientific, Inc.

For more information about this report visit https://www.researchandmarkets.com/r/gea7u2

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.comLaura Wood, Senior Press Managerpress@researchandmarkets.comFor E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900

More here:
In-Vitro Toxicology/Toxicity Testing Market Trends, 2019-2024 - Increasing Focus on Drug Discovery and Personalized Medicine Using In Vitro Methods -...

Global cell isolation market is expected to attain a CAGR of 18.8% during the forecast period.

The global cell isolation market accounted for $4.6 billion revenue in 2017, and it is expected to attain a CAGR of 18.8% during the forecast period (20182023). The demand for cell isolation products and services is increasing due to the rise in requirement for biopharmaceuticals, growing research activities in personalized medicine, and increasing government funding for research.

Cell isolation is the separation of one or multiple types of cells from a heterogenous cell population.

It has become an integral step in biological research, and routine diagnosis and treatment of certain diseases. Some cell types, such as blood cells, naturally exist in a separated form and thus can be isolated by employing centrifugation, whereas some others exist as solid tissues that require specific techniques to isolate the individual cell type.

The global cell isolation market is witnessing growth owing to the rising demand for biopharmaceutical products derived from natural sources, such as plants, animals, and humans, that are easier to manufacture than conventional pharmaceuticals.

Report at:www.psmarketresearch.com/market-ort-sample

The prevalence of neurological diseases, such as Parkinsons disease, amyotrophic lateral sclerosis, spinal cord injury, and autoimmune conditions, namely type 1 diabetes, multiple sclerosis, and Crohns disease is rising. This, coupled with the increasing awareness about these diseases, is impelling the governments of many countries to invest in biomedical research and related technology, thus giving a boost to growth of the cell isolation market and biopharmaceutical production as well.

People in developed countries are shifting toward personalized medicine, owing to their awareness and means to afford personalized treatment, as they can now avail of several reimbursement schemes. The advent of new technologies, such as genetic mapping via next-generation sequencing, which helps in identifying the gene responsible for a specific disease, is boosting the personalized medicine domain.

This growth in the personalized medicine domain is impacting the cell isolation market positively.

GLOBAL CELL ISOLATION MARKET SEGMENTATION

Market Segmentation by Product

Report: http://www.psmarketresearch.com/send-enion-market

Market Segmentation by Cell Type

Market Segmentation by Technique

Market Segmentation by Application

Market Segmentation by End User

This email address is being protected from spambots. You need JavaScript enabled to view it.

Continue reading here:
Growing Biomedical Research and Focus on Personalized Medicine to Aid Cell Isolation Market available in the latest report - WhaTech